Optimal Antiretroviral Management in HIV with Concurrent Antiepileptic Use

Critical Drug Interactions and Management

The American Medical Association recommends against using bictegravir with potent CYP3A4 inducers like carbamazepine, as it significantly reduces bictegravir levels and causes antiretroviral treatment failure 1
Switching to levetiracetam, which does not induce or inhibit cytochrome P450 enzymes, eliminates the drug interaction concern and is a safe and well-tolerated option 4
The guideline-recommended first-line regimen for treatment-naïve adults is bictegravir/emtricitabine/tenofovir alafenamide, with a 92.4% virologic suppression rate at 48 weeks in clinical trials 2, 3, 1

Consult with neurology to coordinate the antiepileptic switch and ensure seizure control during transition, using a loading dose of 1,500mg and maintenance dosing of 500mg twice daily of levetiracetam 4
Initiate bictegravir/emtricitabine/tenofovir alafenamide once levetiracetam is established, and monitor HIV viral load at 4 weeks after starting antiretroviral therapy to confirm virologic response 2, 3
Monitor seizure control during and after the antiepileptic transition, and assess for levetiracetam tolerability at 2-week follow-up 4